Skip to main content

Molecular Pathology of Urinary Bladder Tumors

  • Chapter
  • First Online:
Molecular Surgical Pathology
  • 642 Accesses

Abstract

The unprecedented advances in cancer genetics and genomics have transformed the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, breast, and gynecologic malignancies among others. In sharp contrast, until recently, molecular biomarkers were noticeably absent from the management algorithms of urologic malignancies, including bladder cancer. Integrated genomic analyses of bladder cancer have led to a novel molecular taxonomy of muscle-invasive carcinoma and the identification of predictive markers for newly elucidated targets of therapy. Clinical trials to evaluate these strategies are finally being launched and will hopefully facilitate their adoption in routine practice. The following is an overview of the molecular pathways involved in bladder cancer oncogenesis with a focus on promising candidate biomarkers that may soon make their transition to the realm of clinical management of urothelial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Suggested Reading

  • Al-Ahmadie H, Netto GJ. Updates on the genomics of bladder cancer and novel molecular taxonomy. Adv Anat Pathol. 2020;27:36–43.

    Article  CAS  PubMed  Google Scholar 

  • Al-Ahmadie H, Netto GJ. Molecular pathology of urothelial carcinoma. Surg Pathol Clin. 2021;14:403–14.

    Article  PubMed  PubMed Central  Google Scholar 

  • Al-Obaidy KI, Cheng L. Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. J Clin Pathol. 2021;74:491–5.

    Article  CAS  PubMed  Google Scholar 

  • Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.

    Article  Google Scholar 

  • Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23:2903–10.

    Article  CAS  PubMed  Google Scholar 

  • Cheng L, Davidson DD, Maclennan GT, et al. The origins of urothelial carcinoma. Expert Rev Anticancer Ther. 2010;10:865–80.

    Article  CAS  PubMed  Google Scholar 

  • Cheng L, Zhang S, Alexander R, et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol. 2011a;35:e34–46.

    Article  PubMed  Google Scholar 

  • Cheng L, Zhang S, Maclennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol. 2011b;42:455–81.

    Article  CAS  PubMed  Google Scholar 

  • Cheng L, Lopez-Beltran A, Bostwick DG. Bladder pathology. Wiley-Blackwell: Hoboken, NJ; 2012.

    Book  Google Scholar 

  • Cheng L, Davison DD, Adams J, et al. Biomarkers in badder cancer: translational and clinical implications. Crit Rev Oncol Hematol. 2014;89:73–111.

    Article  PubMed  Google Scholar 

  • Cheng L, Zhang S, Wang L, et al. Fluorescence in situ hybridization in surgical pathology: principles and applications. J Pathol Clin Res. 2017;3:73–99.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cheng L, Zhang S, Wang M, et al. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Hum Pathol. 2023;133:56–75.

    Article  CAS  PubMed  Google Scholar 

  • Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Damrauer JS, Beckabir W, Klomp J, et al. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun. 2022;13:6658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Flaig TW, Tangen CM, Daneshmand S, et al. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021;27:2435–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Flaig TW, Spiess PE, Abern M, et al. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022;20:866–78.

    Article  PubMed  Google Scholar 

  • Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial. J Clin Oncol. 2007;25:2218–24.

    Article  CAS  PubMed  Google Scholar 

  • Kamoun A, de Reynies A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420–33.

    Article  PubMed  Google Scholar 

  • Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.

    Article  CAS  PubMed  Google Scholar 

  • Kouba EJ, Cheng L. Understanding the genetic landscape of small cell carcinoma of the urinary bladder and implications for diagnosis, prognosis and treatment. JAMA Oncol. 2017;3:1570–8.

    Article  PubMed  Google Scholar 

  • Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 2010;70:3463–72.

    Article  CAS  PubMed  Google Scholar 

  • Lindskrog SV, Prip F, Lamy P, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lopez-Beltran A, Cimadamore A, Montironi R, Cheng L. Molecular pathology of urothelial carcinoma. Hum Pathol. 2021;113:67–83.

    Article  CAS  PubMed  Google Scholar 

  • Lotan Y, de Jong JJ, Liu VYT, et al. Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy. J Urol. 2022;207:541–50.

    Article  PubMed  Google Scholar 

  • Magers MJ, Cheng L. Practical molecular testing in a clinical genitourinary service. Arch Pathol Lab Med. 2020;144:277–89.

    Article  CAS  PubMed  Google Scholar 

  • Netto GJ. Molecular diagnostics in urologic malignancies: a work in progress. Arch Pathol Lab Med. 2011;135:610–21.

    Article  CAS  PubMed  Google Scholar 

  • Netto GJ, Cheng L. Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med. 2012;36:372–90.

    Article  Google Scholar 

  • Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology. 2010;42:384–94.

    Article  PubMed  Google Scholar 

  • Netto GJ, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469–82.

    Article  PubMed  Google Scholar 

  • Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2020;21:105–20.

    Article  CAS  PubMed  Google Scholar 

  • Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23:248–5.

    Article  CAS  PubMed  Google Scholar 

  • Sjödahl G, Abrahamsson J, Holmsten K, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2022;81:523–32.

    Article  PubMed  Google Scholar 

  • Sonpavde GP, Mouw KW, Mossanen M. Therapy for muscle-invasive urothelial carcinoma: controversies and dilemmas. J Clin Oncol. 2022;40:1275–80.

    Article  CAS  PubMed  Google Scholar 

  • Thomas J, Sonpavde G. Molecularly targeted therapy towards genetic alterations in advanced bladder cancer. Cancers (Basel). 2022;14:1795.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tran L, Xiao JF, Agarwal N, et al. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21:104–21.

    Article  CAS  PubMed  Google Scholar 

  • van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003;21:1912–21.

    Article  PubMed  Google Scholar 

  • van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58:433–41.

    Article  PubMed  Google Scholar 

  • Warrick JI, Knowles MA, Yves A, et al. Report from the International Society of Urological Pathology (ISUP) Consultation Conference on molecular pathology of urogenital cancers. II. Molecular pathology of bladder cancer: progress and challenges. Am J Surg Pathol. 2020;44:e30–46.

    Article  PubMed  Google Scholar 

  • Yang Y, Miller CR, Lopez-Beltran A, et al. Liquid biopsies in the management of bladder cancer: next-generation biomarkers for diagnosis, surveillance and treatment response prediction. Crit Rev Oncog. 2017;22:389–401.

    Article  PubMed  Google Scholar 

  • Yang Y, Kaimakliotis HZ, Williamson SR, et al. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. Urol Oncol. 2020;38:449–58.

    Article  CAS  PubMed  Google Scholar 

  • Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV 201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:872–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to George J. Netto .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Netto, G.J., Cheng, L. (2023). Molecular Pathology of Urinary Bladder Tumors. In: Cheng, L., Netto, G.J., Eble, J.N. (eds) Molecular Surgical Pathology. Springer, Cham. https://doi.org/10.1007/978-3-031-35118-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-35118-1_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-35117-4

  • Online ISBN: 978-3-031-35118-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics